We hypothesize that the age‑associated enrichment of long cfDNA fragments (>200 bp) carries methylation signatures that function as endogenous danger‑associated molecular patterns (DAMPs). These methylated cfDNA molecules bind and activate Toll‑like receptor 9 (TLR9) on circulating monocytes and neutrophils, triggering NF‑κB‑driven production of pro‑inflammatory cytokines such as MCP‑1 and IL‑6. This creates a positive feedback loop where inflammaging promotes further neutrophil death and cfDNA release, amplifying the signal. Consequently, the methylation pattern of long cfDNA is not merely a biomarker but a mechanistic driver of chronic low‑grade inflammation in aging.

Testable predictions

1. Isolating the >200 bp cfDNA fraction from elderly plasma will induce higher TLR9‑dependent cytokine secretion in primary human monocytes compared with the <150 bp fraction, an effect abolished by TLR9 antagonistic oligonucleotides or DNase I pretreatment.
2. Bisulfite sequencing of the long cfDNA fraction will reveal a methylation signature enriched at the 2 000 age‑related CpG sites previously identified, and synthetic methylated oligonucleotides mimicking these sites will recapitulate the inflammatory response.
3. In vivo, administering a TLR9 inhibitor to aged mice will reduce circulating long cfDNA levels (by decreasing neutrophil extracellular trap formation) and lower plasma MCP‑1 and IL‑6 concentrations, without affecting total cfDNA concentration.
4. Neutrophil‑specific knockdown of DNMT1 in aged mice will diminish methylation of long cfDNA, attenuate TLR9 activation, and ameliorate age‑related inflammatory markers.

Experimental approach

• Plasma from young (3‑month) and aged (24‑month) mice will be fractionated by size using spin columns; each fraction will be quantified by qPCR for a multi‑copy Alu element.
• Human THP‑1 monocytes will be stimulated with equal DNA amounts from each fraction; cytokine release will be measured by ELISA, with parallel experiments using the TLR9 antagonist ODN 2088.
• Long cfDNA will undergo EM‑seq to map methylation; differentially methylated CpGs will be compared to the 48‑CpG aging model.
• Synthetic 200‑bp methylated oligonucleotides representing top‑scoring CpGs will be tested for TLR9 activation in HEK‑Blue™ TLR9 reporter cells.
• In vivo, aged C57BL/6 mice will receive weekly intraperitoneal injections of ODN 2088 or control oligonucleotide for 4 weeks; blood will be drawn for cfDNA size distribution (Fragment Analyzer), cytokine profiling, and neutrophil extracellular trap quantification (citrullinated histone H3 ELISA).
• A parallel cohort will undergo neutrophil‑specific DNMT1 knockdown via CRISPR‑Cas9 ribonucleoprotein electroporation followed by adoptive transfer; outcomes will mirror the pharmacological arm.

Falsifiability If long cfDNA fails to provoke TLR9‑dependent cytokine release despite containing the age‑associated methylation pattern, or if TLR9 inhibition does not reduce inflammaging markers in aged animals, the hypothesis would be refuted. Likewise, demonstrating that short cfDNA fractions are equally or more potent activators of TLR9 would undermine the proposed size‑specific mechanism. Conversely, confirmation of the predictions would support a causal role for methylated long cfDNA in driving inflammaging, positioning it as a therapeutic target beyond a passive biomarker.